Pliant Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D: Tang Capital Management Discloses 9.6% Stake in Pliant Therapeutics, Signals Potential Strategic Engagement
Tang Capital Management and its affiliates have disclosed a 9.6% beneficial ownership stake in Pliant Therapeutics, Inc., indicating an investment purpose and potential future discussions regarding strategic alternatives.